Radiation therapy with or without chemotherapy for head and neck cancer
Part of Cancer clinical trials.
This trial compares two treatments for certain head and neck cancers: radiation therapy alone given more often (hyperfractionated) versus radiation combined with chemotherapy. The goal is to see if one approach is better at controlling the cancer while limiting side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of head and neck cancer in the larynx, hypopharynx, or oropharynx.
- Your cancer must be at a specific stage (T1-2 with lymph node involvement, or T3 with no distant spread).
- You must be able to start radiation therapy within 6 weeks of joining the trial.
- You must have adequate blood counts, liver function, and kidney function.
- You must be 18 years or older and have a good performance status (ECOG 0-1).
- If you are of childbearing age, you must agree to use effective contraception during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a slightly different schedule of radiation (more frequent, smaller doses) can improve treatment for people with large head and neck cancers. It is for patients who are getting radiation as their main treatment, sometimes with chemotherapy as well.
This trial compares two treatments for advanced head and neck cancer in patients who cannot take the drug cisplatin. One group gets radiation plus a targeted drug called cetuximab, the other gets radiation plus standard chemotherapy. The goal is to see which approach works better and is safer for people who are not candidates for cisplatin.
This trial tests a safer radiation plan that may reduce dose to the opposite (other) side of the neck while still treating the cancer spread risk. It uses special mapping to guide treatment and looks at patients whose cancer is already in an involved lymph node on one side.
This trial compares two cisplatin dosing schedules (weekly low-dose vs higher dose less often) given alongside radiation for certain head and neck cancers. It’s testing which schedule works well while keeping side effects manageable during planned, curative-intent radiation.
This trial looks at whether patients with head and neck squamous cell carcinoma who had a good response to chemotherapy and immunotherapy before surgery can safely have less radiation after surgery. It aims to reduce side effects while keeping treatment effective.
This trial tests a combination of re-radiation and chemotherapy with the immunotherapy drug pembrolizumab for people whose head and neck cancer has come back after earlier treatment. It compares this approach to standard immunotherapy or chemo-immunotherapy, and may offer a new option for patients whose cancer has a specific marker (PD-L1).
Hear when a new Head and Neck (HNSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.